Targets › TREM1
1 program from 1 company in 1 trial: 1 Phase 2; Other.
[Isoform 1]: Cell surface receptor that plays important roles in innate and adaptive immunity by amplifying inflammatory responses. Upon activation by various ligands such as PGLYRP1, HMGB1 or HSP70, multimerizes and forms a complex with transmembrane adapter TYROBP/DAP12. (UniProt, Q9NP99)
Open in Phaseline: the race on TREM1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Inotrem | nangibotide Triggering receptor expressed on myeloid cells 1 inhibitor | TREM1 | Phase 2 | Shock, Septic | – |
Shock, Septic (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.